Diagnostic studies Sample Clauses

Diagnostic studies. 2 27.2.1.8 Report on interviews with YOUTH/NMD.
AutoNDA by SimpleDocs
Diagnostic studies. PLEASE LIST THE APPROXIMATE DATE OF TEST, THE NAME OF THE FACILITY WHERE THE TEST WAS PERFORMED, THE NAME OF THE ORDERING PHYSICIAN AND THE RESULTS, IF KNOWN. TEST DATE FACILITY PHYSICIAN RESULTS X-RAY CT SCAN MRI EMG SPI 08/07 0000 Xxxxxxxxx Xxxx XX Xxxxxxx, XX 00000 Patient Name : Account #: MR # : Date : REVIEW OF SYSTEMS Please check any symptoms below that you currently have: HEAD Headaches Trouble with hearing Trouble with eyesight Nasal discharge Hay Fever, frequent sneezing Sinus trouble, post nasal drip THROAT Hoarseness Ulcer of tongue or mouth Trouble with gums or teeth Sore throat LUNGS Asthma, wheezing Cough Cough up blood Tuberculosis Shortness of breath CARDIOVASCULAR High blood pressure Chest pain Irregular beat or palpitation of heart ENDOCRINE Increased thirst, hunger Sudden weight change Sensitive to heat/cold Change in skin, body hair Change in sex drive SKIN Rash Tumor on skin BLADDER AND KIDNEY Frequency urgency or pain with urination Passed blood or kidney stone Trouble starting or stopping of urinary stream STOMACH AND BOWELS Trouble swallowing Abdominal pain, nausea, vomiting Acid Reflux (“Heartburn”) Stomach ulcer/Duodenal ulcer Black bowel movements Diarrhea Constipation Hemorrhoids or rectal itching MUSCULAR Low back pain Joint pain Arthritis Neck pain NERVOUS Backache Balance prolems Numbness or tingling anywhere Weakness Trouble walking MISCELLANEOUS Problems with sleep Dizziness Depression Fatigue Anemia or difficulty with bleeding Sexual problems OTHER? (Please describe) Awaken at night with shortness of breath PROBLEM LIST Please check any of the following below that you have had or currently have a problem with: Alcohol Acquired Brain Injury ALS Asthma Bladder Pain / Spasms Blood Clots Blood in Stool Blood in Urine Cerebral Palsy Cigarettes Current Pregnancy Diabetes Drugs Dysreflexia Frequent UTI Gynecological Problems Hay Fever / Allergies High Blood Pressure HIV (or AIDS) Impaction Kidney Failure Multiple Sclerosis Neurogenic Bladder Neurogenic Bowel Paraplegia Pneumonia Post Polio Psychiatric Problems Respiratory Failure Quadriplegia / Tetraplegia Seizures Skin Problem Xxxxx Bifida Spinal Problems Stroke Ventilator Use SPI 08/07 0000 Xxxxxxxxx Xxxx XX Xxxxxxx, XX 00000 Date Patient Name Medical Record Number YES NO Please fill out this form by checking the appropriate boxes and sign where indicated.
Diagnostic studies. 17 16.3.24 Report of interviews with YOUNfi ADULT.
Diagnostic studies. 1. Carrying out of a comprehensive diagnostic study aimed at assessing all the current arrangements covering the financial, operational, technical, legal and contractual aspects pertaining to the exploitation of oil resources and the management of oil revenues with a view to designing a comprehensive reform program aimed at improving the management of the Borrower’s petroleum sector.
Diagnostic studies. 28 9.1.1.5 Reports on interviews with Youth/NMD; 3 4 5 professionals; medical/dental visits and
Diagnostic studies. 13 7.1.4 Reports on interviews with xxxxxx child;

Related to Diagnostic studies

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Diagnostic procedures to aid the Provider in determining required dental treatment.

  • Trials The Ship shall run the following test and trials:

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Diagnostic Assessment 6.3.1 Boards shall provide a list of pre-approved assessment tools consistent with their Board improvement plan for student achievement and which is compliant with Ministry of Education PPM (PPM 155: Diagnostic Assessment in Support of Student Learning, date of issue January 7, 2013).

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

Time is Money Join Law Insider Premium to draft better contracts faster.